Journal of Clinical Endocrinology & Metabolism, Vol 61, 484-489, Copyright © 1985 by Endocrine Society

ARTICLES

Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women

G Schaison, M George, N Lestrat, A Reinberg and EE Baulieu

The antiprogesterone steroid RU 486 (17 beta-hydroxy-11 beta-4-dimethyl- aminophenyl)17 alpha(1-propynyl)estra-4,9-dien-3-one) was given orally to 32 normally cycling women for 4 days, starting on the fourth day of the luteal phase. Uterine bleeding occurred on the third day of RU 486 administration in all 14 women treated with 100 mg/day, in 7 of the 8 women treated with 50 mg, and in 8 of 10 women receiving 25 mg/day. Premature luteal regression induced by RU 486 occurred in 8 women treated with 100 mg/day, in 3 treated with 50 mg, and in 2 receiving 25 mg/day. Plasma LH was measured every 15 min from 0800-1200 h for 5 days in 17 women. Mean LH levels decreased and pulsatile release disappeared in 7 of the 8 women treated with 100 mg, in 2 of 4 receiving 50 mg, and in 1 of 5 treated with 25 mg. RU 486 had no effect when given to 5 women with anovulatory cycles for 4 days starting on day 18 of the cycle. In conclusion: 1) RU 486, given to normally cycling women at midluteal phase, provokes uterine bleeding. 2) This effect occurs whether or not luteal regression is induced by the compound, indicating that RU 486 acts directly upon the endometrial tissue, very likely at the progesterone receptor level. 3) The drug may impair simultaneously or separately luteal function and gonadotropin secretion in a dose- dependent manner. 4) The lack of antiglucocorticosteroid activity, at the dosage of 100 mg/day, suggests that RU 486 may be useful for fertility control.

This article has been cited by other articles:

				K. Gemzell-Danielsson and L. Marions Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception Hum. Reprod. Update, July 1, 2004; 10(4): 341 - 348. [Abstract] [Full Text] [PDF]

				M. D. Passaro, J. Piquion, N. Mullen, D. Sutherland, S. Zhai, W. D. Figg, R. Blye, and L. K. Nieman Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women Hum. Reprod., September 1, 2003; 18(9): 1820 - 1827. [Abstract] [Full Text] [PDF]

				D. K. Hapangama, H. O. D. Critchley, T. A. Henderson, and D. T. Baird Mifepristone-Induced Vaginal Bleeding Is Associated with Increased Immunostaining for Cyclooxygenase-2 and Decrease in Prostaglandin Dehydrogenase in Luteal Phase Endometrium J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5229 - 5234. [Abstract] [Full Text] [PDF]

				P. W. Ashok, P. T. Wagaarachchi, G. M. Flett, and A. Templeton Mifepristone as a late post-coital contraceptive Hum. Reprod., January 1, 2001; 16(1): 72 - 75. [Abstract] [Full Text] [PDF]

				C. A. VandeVoort, J. W. Overstreet, B. L. Lasley, and D. R. Stewart Effects of Progesterone Receptor Blockers on Human Granulosa-Luteal Cell Culture Secretion of Progesterone, Estradiol, and Relaxin Biol Reprod, January 1, 2000; 62(1): 200 - 205. [Abstract] [Full Text]

				R.R. Greb, L. Kiesel, A.K. Selbmann, M. Wehrmann, G.D. Hodgen, A.L. Goodman, and D. Wallwiener Disparate actions of mifepristone (RU 486) on glands and stroma in the primate endometrium Hum. Reprod., January 1, 1999; 14(1): 198 - 206. [Abstract] [Full Text] [PDF]

				E. Xiao, L. Xia-Zhang, D. Shanen, and M. Ferin Tonic Support of Luteinizing Hormone Secretion by Adrenal Progesterone in the Ovariectomized Monkey Replaced with Midfollicular Phase Levels of Estradiol J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2233 - 2238. [Abstract] [Full Text] [PDF]

				E. Baulieu Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor Science, September 22, 1989; 245(4924): 1351 - 1357. [Abstract] [PDF]